Free Trial

Surmodics (SRDX) Stock Price, News & Analysis

+0.07 (+0.17%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
323,018 shs
Average Volume
127,675 shs
Market Capitalization
$597.78 million
P/E Ratio
Dividend Yield
Price Target

Surmodics MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
19.3% Upside
$50.00 Price Target
Short Interest
3.76% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.90mentions of Surmodics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.51) to $0.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.55 out of 5 stars

Medical Sector

253rd out of 913 stocks

Surgical & Medical Instruments Industry

36th out of 100 stocks

SRDX stock logo

About Surmodics Stock (NASDAQ:SRDX)

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SRDX Stock Price History

SRDX Stock News Headlines

GTCR To Acquire Surmodics - Quick Facts
SurModics earnings: here's what Wall Street expects
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$132.58 million
Cash Flow
$0.79 per share
Book Value
$8.48 per share


Free Float
Market Cap
$597.78 million

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

SRDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SRDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRDX, but not buy additional shares or sell existing shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price target for 2024?

4 brokerages have issued 1-year price targets for Surmodics' stock. Their SRDX share price targets range from $43.00 to $71.00. On average, they expect the company's stock price to reach $50.00 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2024?

Surmodics' stock was trading at $36.35 on January 1st, 2024. Since then, SRDX stock has increased by 15.3% and is now trading at $41.92.
View the best growth stocks for 2024 here

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our SRDX earnings forecast

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings data on Wednesday, May, 1st. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.43. The company earned $31.96 million during the quarter, compared to analyst estimates of $28.79 million. Surmodics had a net margin of 9.44% and a trailing twelve-month return on equity of 13.30%. During the same quarter last year, the company posted ($0.40) earnings per share.

What ETFs hold Surmodics' stock?

ETFs with the largest weight of Surmodics (NASDAQ:SRDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

What guidance has Surmodics issued on next quarter's earnings?

Surmodics issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of -0.670--0.470 for the period, compared to the consensus EPS estimate of -0.940. The company issued revenue guidance of $118.0 million-$120.0 million, compared to the consensus revenue estimate of $119.7 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Who are Surmodics' major shareholders?

Surmodics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.07%), Acadian Asset Management LLC (2.87%), Kennedy Capital Management LLC (0.97%), Jacobs Levy Equity Management Inc. (0.85%), Salem Investment Counselors Inc. (0.85%) and Gamco Investors INC. ET AL (0.50%). Insiders that own company stock include Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRDX) was last updated on 6/13/2024 by Staff

From Our Partners